BMS' Yeryoy and Roche's Zelboraf get final NICE nod
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal for for England and Wales, has published final and binding guidance recommending both Bristol-Myers Squibb's Yervoy (ipillimumab) and Roche's Zelboraf (vemurafenib) for melanoma patients. Both recommendations hinge on a confidential discount offered under a patient access scheme.